
FDA Accepts Regeneron’s sBLA for EYLEA HD for Priority Review
The U.S. Food and Drug Administration (FDA) has accepted Regeneron’s supplemental Biologics License Application (sBLA) for high-dose aflibercept (EYLEA® HD) for priority review, potentially expanding its use in the treatment of macular edema following …